- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad
MIL-OSI: Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Quell Therapeutics Ltd ("Quell"), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical.